Targeted therapy for HER2-negative breast cancer, ‘Ibrance’ acquires approval

Silent for more than ten years. a targeted therapy for Human Epidermal Growth Factor Receptor 2(HER2)-negative breast cancer acquired approval of commercialization in Korea.

On the 29^th, the Ministry of Food and Drug Safety approved Pfizer’s Ibrance Cap 75, 100 & 125mg(generic name: palbociclib).

Ibrance is used to treat HER2-negative progressive & metastatic breast cancer.

As a therapy for ...